Research Paper Volume 16, Issue 11 pp 10033—10062

Figure 10. Associations between DRS and stemness index and clinical drug treatment responses. Correlation analysis of DRS with RNA stem score (A) and renal cancer stem cell markers (CD19, CD44, and SOX2) (B–D). Statistical significance was set at p < 0.05. (E) Boxplots of the estimated IC₅₀ values of chemotherapeutic and targeted agents in the high- and low-DRS groups, including axitinib, imatinib, pazopanib, temsirolimus, cisplatin, and gefitinib. (F, G) Survival analysis for progression-free survival and overall survival of the two DRS groups in patients with ccRCC who were treated with everolimus from the RCC-Braun_2020 cohort. (H) Comparison of DRS of different patients with ccRCC in different remission states after targeted therapy in RCC-Braun_2020 cohort. (ns, p > 0.05; *p < 0.05).